Raymond James Financial Services Advisors Inc. Has $1.36 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Raymond James Financial Services Advisors Inc. boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 47.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,252 shares of the company’s stock after purchasing an additional 5,515 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in TransMedics Group were worth $1,362,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of TMDX. Comerica Bank acquired a new stake in TransMedics Group in the 3rd quarter worth about $34,000. Global Retirement Partners LLC acquired a new stake in TransMedics Group in the 3rd quarter worth about $38,000. Cutler Group LLC CA raised its stake in TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares in the last quarter. Ancora Advisors LLC acquired a new stake in TransMedics Group in the 1st quarter worth about $38,000. Finally, First Horizon Advisors Inc. raised its stake in TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after purchasing an additional 169 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,330 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total transaction of $209,909.70. Following the completion of the transaction, the insider now directly owns 14,375 shares in the company, valued at approximately $1,295,043.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 2,330 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total transaction of $209,909.70. Following the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the sale, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The disclosure for this sale can be found here. Insiders sold a total of 125,408 shares of company stock worth $10,606,501 in the last three months. 6.70% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

TMDX stock opened at $91.82 on Friday. The company has a 50 day simple moving average of $82.77 and a 200 day simple moving average of $72.03. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of -119.25 and a beta of 1.99. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $99.63. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm’s quarterly revenue was up 158.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.21) EPS. Research analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Morgan Stanley boosted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Oppenheimer boosted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Finally, Piper Sandler assumed coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.